Comparison of Mean Overall Survival (OS) and Radiographic Progression Free Survival (RPFS) Based on Matching Adjusted Indirect Comparison of Abiraterone Acetate and Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Chemotherapy Naïve Patients.

Dearden, L; Majer, I; Heeg, B; Liwing, J; Sandstrom, K; Diels, J

Dearden, L; Majer, I; Heeg, B; Liwing, J; Sandstrom, K; Diels, J.

Afiliação

Dearden L; Janssen, High Wycombe, UK.
Majer I; Pharmerit International, Rotterdam, The Netherlands.
Heeg B; Pharmerit International, Rotterdam, The Netherlands.
Liwing J; Janssen-Cilag AB, Sollentuna, Sweden.
Sandstrom K; Janssen-Cilag AB, Sollentuna, Sweden.
Diels J; Janssen Research & Development, Beerse, Belgium.

Value Health ; 17(7): A616, 2014 Nov.

Article em En | MEDLINE | ID: mdl-27202160

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Value Health Assunto da revista: FARMACOLOGIA Ano de publicação: 2014 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google